100s of titles, one news app for just $10 a month.
Dive Deeper:
Analysts Expect Clarity Imminent On Intercept's NASH Story
RBC Capital Markets writes that following the Advanz deal, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) should be well-capitalized into make-or-break upcoming readouts for obeticholic acid…
Arcellx Doses First Patient in Phase 1 study of ACLX-001 in Relapsed or Refractory Multiple Myeloma
Arcellx, Inc. (NASDAQ: ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical…
MoonLake Immunotherapeutics Begins Sonelokimab Phase 2 trial In Hidradenitis Suppurativa (HS)
MoonLake Immunotherapeutics AG (NASDAQ: MLTX) dosed first patient in the Phase 2 clinical trial evaluating sonelokimab, for patients with moderate-to-severe hidradenitis…
NGM Bio Initiates NGM438 Phase 1/1b trial for advanced solid tumors
NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ: NGM) initiated a Phase 1/1b clinical study of its drug candidate NGM438 for the treatment…
One subscription that gives you access to news from hundreds of sites
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in CHIRON Phase 1/2a Trial for Advanced NSCLC
Achilles Therapeutics plc (NASDAQ: ACHL) announced that the first patient has been dosed with personalized clonal neoantigen-reactive T cells, or…
Get all your news in one place
Latest Technology news:
Mini Countryman EV Accurately Rendered Ahead Of 2023 Release
The next-gen Mini Countryman will offer a fully electric variant. It will also be significantly larger than the current iteration.
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
Tesla Model Y: True Cost Of Ownership After 2 Years
How much does it really cost to own a Model Y? YouTuber Ryan Shaw lets us know in his latest…
Watch Toyota bZ4X AWD Fast Charging Test: 0-80% SOC Took One Hour
A fast-charging test of a 2022 Toyota bZ4X AWD, equipped with a 72.8 kWh battery, disappoints as the car required…
Can Traditional Automakers Compete With Tesla? Model Y Compared To Rivals
How does the Tesla Model Y compare with its European competition? Matt from Carwow finds out in the channel's latest…
Ford Unloads Another 7 Million Rivian Shares As Stock Plummets
Rivian stock continues to fall as Ford continues to sell more and more of it.
From analysis to good news, read the world’s best news in one place
Hyundai Plug-In Car Wholesale Shipments Reach New Record In April 2022
Hyundai's plug-in electric car sales increased significantly in April reaching a new record level of 19,521 wholesale shipments, including 9,844…
2022 game releases: The biggest games launching this summer and fall
'Starfield', 'Breath of the Wild 2', and other huge games have been delayed until 2023, but 2022 still has great…

First Patient Dosed in Phase 2 Study of Intercept's OCA and Bezafibrate Combination for Primary Biliary Cholangitis

By Ragothaman Srinivasan

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) dosed first patient in a Phase 2 study evaluating a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF) for the treatment of patients with primary biliary cholangitis (PBC).

The study is expected to recruit approximately 60 patients in the United States.

Further, a second Phase 2 study is currently active in Europe, evaluating different dosing regimens of the OCA-BZF combination.

M. Michelle Berrey, Chief Medical Officer, said, ”We believe OCA and BZF have synergistic mechanisms of action that can potentially provide additional benefits to people with PBC when used in combination. Additionally, both medicines have been shown to help lower the key biochemical measures that predict long-term outcomes in PBC. BZF has also been associated with improvements in pruritus, a potential benefit we are exploring in our Phase 2 program.”

In the on-going phase 1 study in the United States, healthy adult subjects are being tested for different dosage combinations.

Intercept Pharmaceuticals is currently trading down at $18.58.

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
Analysts Expect Clarity Imminent On Intercept's NASH Story
RBC Capital Markets writes that following the Advanz deal, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) should be well-capitalized into make-or-break upcoming readouts for obeticholic acid…
Arcellx Doses First Patient in Phase 1 study of ACLX-001 in Relapsed or Refractory Multiple Myeloma
Arcellx, Inc. (NASDAQ: ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical…
MoonLake Immunotherapeutics Begins Sonelokimab Phase 2 trial In Hidradenitis Suppurativa (HS)
MoonLake Immunotherapeutics AG (NASDAQ: MLTX) dosed first patient in the Phase 2 clinical trial evaluating sonelokimab, for patients with moderate-to-severe hidradenitis…
NGM Bio Initiates NGM438 Phase 1/1b trial for advanced solid tumors
NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ: NGM) initiated a Phase 1/1b clinical study of its drug candidate NGM438 for the treatment…
One subscription that gives you access to news from hundreds of sites
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in CHIRON Phase 1/2a Trial for Advanced NSCLC
Achilles Therapeutics plc (NASDAQ: ACHL) announced that the first patient has been dosed with personalized clonal neoantigen-reactive T cells, or…
Get all your news in one place